Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Starting treatment news

Show

From To
Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

Biktarvy Showed High Efficacy and High Barrier to Resistance Through 96 Weeks

Published
01 November 2018
From
Gilead press release
Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir

Dolutegravir-based treatment was no more effective than treatment based on a 400mg dose of efavirenz, a randomised trial conducted in Cameroon has found. However, almost half

Published
01 November 2018
By
Keith Alcorn
Bictegravir matches dolutegravir in first-line treatment

A triple combination containing the new integrase inhibitor bictegravir proved just as effective as a dolutegravir-based combination in suppressing viral load over 96 weeks, but people taking bictegravir

Published
31 October 2018
By
Keith Alcorn
Two-drug protease inhibitor treatment as effective as three-drug treatment – and fewer stop due to side-effects

Antiretroviral treatment with a boosted protease inhibitor and one other drug is just as effective as three-drug antiretroviral therapy containing a boosted protease inhibitor but results in

Published
30 October 2018
By
Keith Alcorn
Studies confirm long-term effectiveness of new single-tablet regimens

The newest once-daily, all-in-one HIV combination pills can maintain undetectable viral load for two years and counting, according to a set of studies presented at IDWeek 2018

Published
18 October 2018
By
Liz Highleyman
Rapid Initiation of HIV Care: Assessing Safety and Efficacy

Discussion with Gregory Huhn, MD

Published
16 October 2018
From
Infectious Disease Advisor
Doravirine combination works well as a switch option

A combination pill containing doravirine (Delstrigo) maintains undetectable viral load in people with well-controlled HIV who switched therapy, and continues to provide sustained viral suppression at 96

Published
08 October 2018
By
Liz Highleyman
PET Scans May Predict Who Gets Inflammatory Reaction to HIV Treatment Start

The imaging method known as a PET scan may be able to predict who among those starting antiretroviral (ARV) treatment with an immune system highly damaged by HIV will develop HIV-associated immune reconstitution syndrome (IRIS).

Published
26 September 2018
From
Poz
Two new doravirine pills approved in US

The US Food and Drug Administration (FDA) has approved two new products containing the next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine. These products are also under review by

Published
12 September 2018
By
Liz Highleyman
Indonesia: tackling HIV in one of the world’s fastest-growing epidemics

A prospective study that recruited a significant proportion of people newly diagnosed with HIV in four locations in Indonesia and offered them immediate antiretroviral therapy (ART)

Published
04 September 2018
By
Gus Cairns

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.